Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB122 in Early-Stage Parkinson's Disease with LRRK2 Variants
NCT05418673Phase 3Terminated
- Sponsor
- Biogen
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of BIIB122 in Parkinson's disease (PD), sponsored by Biogen. Started Aug 2022; status: terminated.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05418673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418673.